Alkoholpolitik und Volksgesundheit

USA: Doctors‘ role in drug studies criticized

Freitag 4. Juni 2010 von htm

Some recommend drugs, vouch for studies but don’t see raw numbers
Richard Page thinks Multaq is an excellent new drug for treating atrial fibrillation, a type of irregular heartbeat that affects more than 2 million Americans.
And Page, chairman of the department of medicine at the University of Wisconsin School of Medicine and Public Health, should know. He co-authored a large, international study that led to the drug’s approval by the Food and Drug Administration last year, a move that could mean hundreds of millions in sales for Sanofi-Aventis, the company that makes the drug.
But in putting his name on the influential paper, Page allowed Sanofi-Aventis to dictate the terms. He vouched for the accuracy and completeness of the study despite not seeing the raw data. The company, which paid for the study, collected that information and performed the analysis without an external audit for accuracy or completeness.
Page says it comes down to trusting the drug company. (Source: Harvard World Health News, 6/3/10) jsonline.com, 5/30/10 Comment: The same problem with the alcohol industry and their studies.

Be Sociable, Share!

Dieser Beitrag wurde erstellt am Freitag 4. Juni 2010 um 12:20 und abgelegt unter Alcohol industry, Allgemein, Global, Health, Publications, Research. Kommentare zu diesen Eintrag im RSS 2.0 Feed. Die Kommentare sind derzeit geschlossen, aber sie können einen Trackback auf Ihrer Seite einrichten.

Kommentare sind geschlossen.

Powered by Gb-rugs.com - Rugs & Carpets

Get Adobe Flash player